INS and familial pancreatic carcinoma: On the other hand, elevated risk of pancreatic cancer was observed with insulin secretagogue use (n = 5; RR = 1.26; 95% CI = 1.01–1.57; Table 7), and elevated risks of liver (n = 7; RR = 1.74; 95% CI = 1.08–2.80; Table 6) and pancreatic cancers (n = 8; RR = 2.41; 95% CI = 1.08–5.36; Table 7) were observed with insulin use.